Approval is not adoption
Even when China-only evidence supports a European approval, routine use is not automatic. National reimbursement may lag. HTA bodies may value the same evidence differently. Clinicians may have familiar alternatives. The European commercial partner may also need to build confidence in a crowded indication. This is where observing China's domestic market becomes useful. The China SCLC data are not a forecast of European shares. They are a live example of what happens when multiple credible choices become available quickly: treatment fragments, apparently similar products need genuine differentiation, and efficacy competes with access, familiarity, hospital availability and price. The market also does not stop at first line. During an industry satellite symposium at ESMO 2026, Professor Giuseppe Banna stressed that many patients with extensive-stage SCLC never reach a later line, making the initial decision unusually consequential. With maintenance intensification and T-cell engagers entering the pathway, the competitive question is shifting from which medicine wins first line to which initial strategy brings more patients into maintenance and preserves the opportunity for subsequent treatment. The unit of competition is becoming the sequence, not just the product. This creates an opportunity for a more revealing Ipsos analysis: among patients observed in second line, how many received first-line maintenance and how many moved directly from induction? Which first-line approaches are associated with reaching maintenance or a novel later-line treatment?

The unit of competition is becoming the sequence, not just the product.
